Lactulose in the treatment of hepatic encephalopathy: New evidence for an old modality

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 8, 2012, Pages 1262-1263

  Jia, Ji Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; LACTULOSE; PLACEBO; RIFAXIMIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; LIVER CIRRHOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

EID: 84864304961     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07177.x     Document Type: Editorial

References (13)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT; the Members of the Working Party. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
2. Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl. 2007; 13: 1366-71.
3. Shawcross DL, Olde Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab. Brain Dis. 2005; 20: 169-79.
4. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.
5. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose. J. Gastroenterol. Hepatol. 2012; ; 27: 1329-35.
6. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur. J. Gastroenterol. Hepatol. 2011; 23: 1250-7.
7. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010; 51: 1062-9.
8. Bass NM, Mullen KD, Sanyal A etal. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 2010; 362: 1071-81.
9. Bajaj JS, Riggio O. Drug therapy: rifaximin. Hepatology 2010; 52: 1484-8.
10. Foster KJ, Lin S, Turck CJ. Current and emerging strategies for treating hepatic encephalopathy. Crit. Care Nurs. Clin. North Am. 2010; 22: 341-50.
11. Kircheis G, Fleig WE, Görtelmeyer R, Grafe S, Häussinger D. Assessment of low-grade hepatic encephalopathy: a critical analysis. J. Hepatol. 2007; 47: 642-50.
12. Hassanein T, Blei AT, Perry W etal. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am. J. Gastroenterol. 2009; 104: 1392-400.
13. Bajaj JS, Cordoba J, Mullen KD etal.; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). The design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment. Pharmacol. Ther. 2011; 33: 739-47.